Salubris Pharmaceuticals Ltd.

We are pleased to share the latest clinical progress of Salubris’ novel oncology candidate JK06, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. This milestone further reflects Salubris’ continued commitment to advancing innovative oncology therapies and addressing unmet clinical needs for patients worldwide. #SalubrisPharma #JK06 #ASCO2026 #Oncology #OncologyResearch #ClinicalDevelopment #ClinicalTrials #ADC #AntibodyDrugConjugate #5T4 #SolidTumors #NSCLC #BreastCancer #DrugDevelopment #BiopharmaInnovation #CancerResearch #InnovativeMedicine #GlobalInnovation #PatientBenefit #BusinessDevelopment #Partnering #StrategicPartnership #GlobalPartnerships #CollaborationOpportunities #PharmaPartnering #BiotechPartnership #InnovationPartnership #OncologyBD #ADCPartnering #GlobalHealthcare

🚀 Salubris’ Innovative siRNA Therapeutic SAL0195 Clinical Trial Application Accepted for the Treatment of Lipid-Related Diseases 🔬Recently, Salubris announced that the clinical trial application for its independently developed innovative siRNA therapeutic, SAL0195 Injection (project code: SAL0195), has been accepted for review for the treatment of lipid-related diseases [1]. 🔬SAL0195 is a highly potent and highly specific siRNA therapeutic designed against a lipid-associated target and has demonstrated long-lasting target knockdown effects lasting up to 140 days with a single dose in preclinical monkey models [1]. 🔬If successfully developed and approved for marketing, SAL0195 is expected to provide a new therapeutic option for patients with lipid disorders, address unmet clinical needs, and further strengthen the Company’s innovative pipeline in the cardiovascular–kidney–metabolic (CKM) disease area, with cardiovascular and cerebrovascular disease management as a core focus. 🗺️About siRNA Therapeutics [2] Small interfering RNA (siRNA) therapeutics typically consist of short double-stranded RNA molecules. Through the RNA interference (RNAi) mechanism, they induce sequence-specific post-transcriptional silencing of disease-related target messenger RNA (mRNA), thereby enabling a precise therapeutic approach. By selectively targeting disease-related genes, siRNA therapeutics may offer sustained pharmacological effects and less prone to drug resistance, as well as the potential for reduced dosing frequency. These characteristics may help improve treatment adherence and support the development of new therapeutic approaches for chronic diseases. #SalubrisPharma #SAL0195 #siRNA #RNATherapeutics #RNAi #LipidDisorders #CardiovascularHealth #MetabolicDiseases #CKM #CKMInnovation #Hyperlipidemia #DrugDevelopment #ClinicalResearch #InnovativeMedicine #Biopharma #PharmaceuticalInnovation #PrecisionMedicine #NextGenTherapies #LongActingTherapies #CardioMetabolicHealth #GlobalHealth #PatientCentricInnovation #RDPipeline #LifeSciences #HealthcareInnovation #BusinessDevelopment #PharmaBD #Licensing #StrategicPartnerships #GlobalPartnerships #BusinessCollaboration #InnovationPartnerships #LicensingOpportunities #BiotechPartnerships

🌍 News from Salubris! 🌍 We are delighted to invite you to meet us at CPHI Shanghai 2026 – one of the world’s leading pharmaceutical industry events. 📅 Date: 16–18 June, 2026 📍 Location: Shanghai, China 📌 Booth: E1B57 🤝 We warmly welcome you to visit our booth, connect with our team, and discover more about Salubris’ commitment to advancing pharmaceutical solutions worldwide. #CPHI #CPHIChina #CPHIShanghai #Salubris #PharmaceuticalIndustry #Biopharma #Biotech #HealthcareInnovation #GlobalHealthcare #DrugDevelopment #Licensing #BusinessDevelopment #StrategicPartnership #API #Biosimilars #Innovation #PharmaPartners #LifeSciences #GlobalExpansion #ChinaPharma

🚀 Salubris’ Cyclic Peptide Drug SAL0167 Clinical Trial Application Accepted for Review for the Treatment of Hyperlipidemia 🔬Recently, Salubris announced that the clinical trial application for its independently developed innovative drug SAL0167 tablets (project code: SAL0167) has been accepted for review for the treatment of hyperlipidemia[1]. 🔬SAL0167 is a cyclic peptide drug with proprietary intellectual property rights owned by Salubris. As a cyclic peptide, SAL0167 exhibits high affinity and specificity toward its target, demonstrating potential as a preferred therapeutic option for hypercholesterolemia, particularly for patients requiring intensive lipid-lowering treatment. 🔬If successfully developed and approved for marketing, SAL0167 is expected to provide patients with a new therapeutic option, improve treatment adherence, address unmet clinical needs, and further enrich Salubris’ innovative pipeline in the cardio–kidney–metabolic (CKM) disease area with a core focus on cardiovascular and cerebrovascular diseases. 🗺️About Cyclic Peptides [2–3] Cyclic peptide drugs represent an emerging therapeutic modality positioned between small-molecule drugs and antibody-based therapeutics, combining key advantages of both categories: they retain the high activity, strong selectivity, and favorable safety profile commonly associated with antibody drugs, while also offering notable features of small-molecule drugs, including relatively lower manufacturing costs, good stability, and the potential for oral administration. These unique characteristics position cyclic peptides as a promising emerging modality in modern drug discovery and development. #SalubrisPharma #SAL0167 #CyclicPeptide #Hyperlipidemia #Hypercholesterolemia #CKMInnovation #CardiovascularHealth #LipidManagement #DrugDevelopment #ClinicalResearch #PharmaceuticalInnovation #InnovativeMedicines #BusinessDevelopment #GlobalPartnership

🎉 Sharing the latest clinical update on Salubris’ innovative oncology asset JK06, presented at the American Association for Cancer Research 2026 Annual Meeting. #JK06 #Oncology #CancerResearch #ClinicalData #AACR2026 #ADC #Biopharma #AntibodyDrugConjugates #TargetedTherapy #PrecisionMedicine #TranslationalMedicine #DrugDevelopment #ClinicalResearch #SolidTumors #LungCancer #BreastCancer #NSCLC #OncologyInnovation #BusinessDevelopment #Licensing #GlobalPartnerships #BiotechDeals #PharmaBD #Collaboration #InnovationDriven #RDPipeline

🎉 Exploring the potential of next-generation antihypertensive therapy: Phase I data of SAL0132 highlights durable AGT suppression and long-acting efficacy, addressing key unmet needs in hypertension management. #SalubrisPharma #siRNA #NextGenTherapies #CKM #ChronicDisease #CardioRenalMetabolic #ClinicalTrials #DrugDevelopment #RAAS #AGT #TargetedTherapy #BusinessDevelopment #GlobalPartnerships  

🚀 We’re Hiring: Business Development (BD) Manager – India 🗺️ At Salubris Pharmaceuticals, we are expanding our global footprint and seeking an experienced BD leader to drive strategic growth in the US, Europe, India, etc. Salubris is a 10-billion-USD, global integrated, innovative pharma group, with over 27 years of experience in chronic disease management, serving more than 60 countries. 🔹 Key Responsibilities 1. Strategic Partnerships & Market Expansion: Drive end-to-end licensing deals in the US, Europe, India, etc. and strategic partnerships while building key stakeholder networks and advancing BD partnership. 2. Market Intelligence & Execution: Deliver actionable market insights and drive market access and cross-functional execution to support successful product commercialization. 🔹 Qualifications 1. Education: Bachelor’s degree or above (Master, phD, MBA preferred) in Pharmacy, Medicine, Life Sciences or Business related. 2. Experience: 6+ years in pharmaceutical BD with proven BD experience in the US, Europe and India, etc. 3. Language: Fluent in English for international business communication. 4. Capabilities: Strong negotiation, strategic thinking, and project execution skills. 5. Market Expertise: Deep understanding of pharmaceutical markets, regulatory landscape, and competitive dynamics across the US, Europe, and India. 6. Business Relationship: Able to develop and maintain business relationship including those on the personal level. 7. Team: Able to efficiently manage team work load. 🌍 Why Join Us? Be part of a fast-growing, innovation-driven pharmaceutical company expanding globally across CKM and specialty therapeutics, with strong integration across R&D, manufacturing, and commercialization. 📩 Interested or know someone suitable? Please send your CV to wangyanan@salubris.com and zhangbin02@salubris.com with the subject line BD_India_LinkedIn #Hiring #NowHiring #JoinOurTeam #CareerOpportunity #WeAreHiring #HiringIndia #JobsInIndia #IndiaJobs #PharmaJobs #PharmaCareers #PharmaceuticalIndustry #LifeSciences #HealthcareJobs #Biopharma #DrugDevelopment #PharmaBD #IndiaPharma #GlobalExpansion #BusinessDevelopment

🎉Salubris’ innovative drug SAL0145 has been approved for clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). 🔬Recently, Shenzhen Salubris Pharmaceuticals Co., Ltd. (the “Company”) received a Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), granting approval for the it’s self-developed innovative drug SAL0145 injection (project code: SAL0145) to initiate clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) [1]. 🔬SAL0145 is an siRNA (small interfering RNA) therapeutic independently developed by the Company with proprietary intellectual property rights. Preclinical studies have demonstrated its potential for the treatment of MASH. If successfully developed and approved for marketing, it is expected to provide a new therapeutic option for patients, address unmet clinical needs, and further enrich the Company’s innovative pipeline in the cardio-kidney-metabolic (CKM) disease area. 🗺️About MASH [2] Metabolic dysfunction-associated steatohepatitis (MASH) is one of the progressive forms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects approximately 30% of the global adult population. Without timely intervention or treatment, MASH may progress to cirrhosis or even hepatocellular carcinoma, posing serious threats to patients’ health. 🗺️About siRNA therapeutics [3] Small interfering RNA (siRNA) typically consists of short double-stranded RNA molecules composed of base pairs. Through the RNAi mechanism, siRNA specifically silences disease-causing target mRNA at the post-transcriptional level, thereby achieving precise therapeutic effects. siRNA therapeutics can precisely target pathogenic genes, while offering advantages such as a low risk of resistance and prolonged therapeutic effects, reduced dosing frequency and significantly improved patient compliance. These features position siRNA drugs as a promising modality with the potential to transform traditional treatment approaches, particularly in chronic disease management. 🗺️About CKM [4] In October 2023, the American Heart Association issued a Presidential Advisory on cardio-kidney-metabolic (CKM) syndrome, defining CKM syndrome as a health disorder driven by the pathophysiological interplay among obesity, diabetes mellitus (DM), chronic kidney disease (CKD), and cardiovascular disease (CVD), representing a systemic condition. #ClinicalTrials #DrugDevelopment #SalubrisPharm #Innovation #MASH #ChronicDisease #siRNA #HealthcareInnovation #GlobalHealth #LifeSciences #Biopharma #BusinessDevelopment #GlobalExpansion #StrategicPartnerships

🎉Salubris’ self-developed innovative drug SAL0150 has been approved for clinical trials for the treatment of conditions including type 2 diabetes and obesity. 🔬Recently, Shenzhen Salubris Pharmaceuticals Co., Ltd. (referred to as the “Company”) received the Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), granting approval for the Company’s independently developed innovative drug SAL0150 tablets (project code: SAL0150) to initiate clinical trials in indications including glycemic control in patients with type 2 diabetes mellitus, overweight or obesity, and type 2 diabetes mellitus complicated with peripheral arterial disease accompanied by intermittent claudication [1].  🔬SAL0150 is an orally administered, long-acting drug with proprietary intellectual property rights owned by the company, and it is expected to achieve a dosing frequency of at least once weekly [2]. If successfully developed and approved for marketing, SAL0150 is expected to provide a new therapeutic option for a broader patient population, address unmet clinical needs, and further enrich the company’s innovative pipeline in the cardio–kidney–metabolic (CKM) disease area. 🗺️About CKM [2] In October 2023, the American Heart Association (AHA) issued a Presidential Advisory on cardio–kidney–metabolic (CKM) syndrome, defining it as a systemic disorder arising from the pathophysiological interplay among obesity, diabetes mellitus (DM), chronic kidney disease (CKD), and cardiovascular disease (CVD). #InnovativeDrugs #CardioKidneyMetabolic #OralTherapeutics #LongActing #BusinessDevelopment #GlobalPartnership #LifeSciencesNetwork #TypeIIDiabetes #IND #MetabolicDisease

🎉 As we continue to build a more connected global presence, it’s worth revisiting some of the meaningful progress from Salubris Biotherapeutics about JK06. #GlobalCollaboration #InnovationDriven #ScienceInAction #PharmaInnovation #ClinicalDevelopment #RAndD https://lnkd.in/gt3SG3Cv